Manufacturing RNA or
oligo-based therapeutics?
We're all about that
Meet the nucleic acid therapeutics team at Cytiva
Introducing nucleic acid therapeutics: a newly formed business unit at Cytiva. Nucleic acids, in the form of oligonucleotides, mRNA, or mRNA variants, can be a transformative modality. We know that oligo synthesis has been around for over 20 years, but oligonucleotides are now hitting the market in large numbers.
At Cytiva, the new team is here to support you. We can help you throughout the manufacturing workflow for oligonucleotides and the purification of mRNA drug substances. And, in collaboration with our colleagues at Precision Nanosystems, we’ll help you bring mRNA lipid nanoparticle therapeutics to market.
There’s a lot of work to do. Let’s get going.
A neighbor. A family. A global community.
No matter who’s at the end of your pipeline, Scott Ripley and our nucleic acid therapeutics team are ready to help you reach them.
Meet Linda Mathiasson
She works directly with our customers and scientists on the front lines of therapeutic development.
Katarina Stenklo pulls back the curtain...
On rapid scale-up of nucleic acid therapeutics.
The future is bright...
For mRNA, oligonucleotides, and other nucleic acid therapeutics. Lucy Cook shares insights on how our team can help manufacturers seize the moment.
Contact our specialists to learn more about our solutions for nucleic acid therapeutics
Privacy | Terms | Trademarks | Legal | Contact
© 2023 Cytiva